

UC San Diego

UC San Diego Previously Published Works

Title

Clinical utility of an antibody-free LC-MS method to detect brain amyloid deposition in cognitively unimpaired individuals from the screening visit of the A4 Study

Permalink

<https://escholarship.org/uc/item/2gm1k184>

Journal

Alzheimer's & Dementia Diagnosis Assessment & Disease Monitoring, 15(2)

ISSN

2352-8729

Authors

Allué, José Antonio
Pascual-Lucas, María
Sarasa, Leticia
[et al.](#)

Publication Date

2023-04-01


DOI

10.1002/dad2.12451

Peer reviewed

RESEARCH ARTICLE

Clinical utility of an antibody-free LC-MS method to detect brain amyloid deposition in cognitively unimpaired individuals from the screening visit of the A4 Study

José Antonio Allué¹  | María Pascual-Lucas¹ | Leticia Sarasa¹ | Sergio Castillo¹ | Manuel Sarasa^{1,†} | María Eugenia Sáez² | Sara Abdel-Latif³ | Robert A. Rissman^{3,4} | Jose Terencio¹

¹Araclon Biotech-Grifols, Zaragoza, Spain

²Caebi. Centro Andaluz de Estudios Bioinformáticos, Sevilla, Spain

³Alzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego, California, USA

⁴Department of Neurosciences, University of California, San Diego, La Jolla, California, USA

Correspondence

José Antonio Allué, Araclon Biotech-Grifols,
Vía Hispanidad 21, 50009, Zaragoza, Spain.
Email: jallue@araclon.com

[†]Deceased May 27, 2020

Funding information

NIH/NIA, Grant/Award Numbers: AG058252,
AG073979, AG051848, AG057437,
AG010483

Abstract

INTRODUCTION: This study explored the ability of plasma amyloid beta (A β)₄₂/A β ₄₀ to identify brain amyloid deposition in cognitively unimpaired (CU) individuals.

METHODS: Plasma A β was quantified with an antibody-free high-performance liquid chromatography tandem mass spectrometry method from Araclon Biotech (ABtest-MS) in a subset of 731 CU individuals from the screening visit of the Anti-Amyloid Treatment in Asymptomatic Alzheimer's (A4) Study, to assess associations of A β ₄₂/A β ₄₀ with A β positron emission tomography (PET).

RESULTS: A model including A β ₄₂/A β ₄₀, age, apolipoprotein E ϵ 4, and recruitment site identified A β PET status with an area under the curve of 0.88 and an overall accuracy of 81%. A plasma-based pre-screening step could save up to 42% of the total number of A β PET scans.

DISCUSSION: ABtest-MS accurately identified brain amyloid deposition in a population of CU individuals, supporting its implementation in AD secondary prevention trials to reduce recruitment time and costs. Although a certain degree of heterogeneity is inherent to large and multicentric trials, ABtest-MS could be more robust to pre-analytical bias compared to other immunoprecipitation mass spectrometry methods.

KEYWORDS

Anti-Amyloid Treatment in Asymptomatic Alzheimer's (A4) Study, Alzheimer's disease, amyloid beta, A β ₄₂/A β ₄₀, blood biomarkers, clinical trials, mass spectrometry, pre-screening

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2023 The Authors. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring* published by Wiley Periodicals, LLC on behalf of Alzheimer's Association.

HIGHLIGHTS

- Plasma amyloid beta (A β)₄₂/A β ₄₀ accurately identified brain A β deposition in cognitively unimpaired individuals from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's (A4) Study.
- The inclusion of the recruitment site in the predictive models has a non-negligible effect.
- A plasma biomarker-based model could reduce recruitment costs in Alzheimer's disease secondary prevention trials.
- Antibody-free liquid chromatography mass spectrometry methods may be more robust to pre-analytical variability than other platforms.

1 | BACKGROUND

Alzheimer's disease (AD), the most common form of dementia, is characterized by a long preclinical stage in which individuals do not show clinical symptoms though neuropathological alterations (amyloid plaques and neurofibrillary tangles) are already present.¹⁻⁴ It is widely accepted that disease-modifying therapies are likely more effective during these very first stages of AD before extensive neurodegeneration and overt clinical symptoms arise. Accordingly, clinical trials in AD are currently being conducted in earlier stages of the disease,⁵⁻⁷ that is, in preclinical individuals with evidence of brain amyloid deposition.

Accurate screening procedures for brain amyloidosis, such as positron emission tomography (PET) imaging or cerebrospinal fluid (CSF) measurements, are expensive and invasive, and impose a significant monetary burden for study sponsors. This is especially relevant in clinical trials targeting preclinical populations in which the prevalence of brain amyloid deposition is estimated to be \approx 25%.⁸ On the other hand, blood assays are gaining increasing popularity in the clinical research framework.^{4,9-14} These blood tests are non-invasive, cost effective (compared to CSF and PET), and represent limited physical risk for the patient. Some of these blood biomarkers also show high accuracy for the discrimination of amyloid beta (A β) or tau abnormalities in the brain, years before symptoms start. All these characteristics make blood assays useful tools for participant pre-screening in clinical trials, along with other applications, significantly reducing the necessary number of PET scans or lumbar punctures.

Plasma A β ₄₂/A β ₄₀ ratio is a well-established marker for amyloidosis.¹⁵⁻¹⁷ However, the measurement of this ratio is not straightforward due to the chemical nature of both peptides. Some recent work calls plasma A β ₄₂/A β ₄₀ ratio robustness into question due to the small differences between A β PET positive (+) and negative (-) individuals and the inherent overlap in the distribution of the biomarker values between groups.^{18,19} According to this, it seems clear that high accuracy and robust methods should be used for A β ₄₂ and A β ₄₀ quantitation in plasma. This is particularly important in large and multicentric studies in which pre-analytical factors may

significantly contribute to overall variability. Even after the implementation of standardized operating protocols for sample collection, handling, and storage, a certain degree of pre-analytical variability is always present.^{20,21}

Araclon Biotech developed an antibody-free high-performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS) method (ABtest-MS) for the quantification of plasma A β ₄₂/A β ₄₀. This innovative procedure includes a direct extraction of A β peptides from plasma without involving any immunoprecipitation (IP) or digestion step, which significantly reduces time and costs, resulting in a more affordable and accessible assay.^{11,22,23}

In this work, we investigate the ability of plasma A β ₄₂/A β ₄₀ ratio measured with ABtest-MS to identify brain amyloid deposition in a subset of cognitively unimpaired (CU) individuals from the second screening visit of the Anti-Amyloid Treatment in Asymptomatic Alzheimer's (A4) Study. Moreover, because recent findings have revealed the impact of blood processing protocols on the ability of plasma A β ₄₂/A β ₄₀ to predict amyloid PET positivity in samples from the same study,²⁴ we aim to expand this observation and highlight the influence of pre-analytical variables in large multicentric studies.

2 | METHODS

2.1 | Study participants

The A4 Study (ClinicalTrials.gov identifier: NCT02008357) is a 240-week trial testing whether solanezumab (Eli Lilly & Company) can slow cognitive decline associated with AD at the preclinical stage of the disease. Detailed information describing the study design can be found elsewhere.²⁵⁻²⁷ Briefly, participants eligible for screening were 65 to 85 years of age, assessed to be cognitively normal, living independently, and have a study partner to provide information on daily life cognitive function on an annual basis. More than 4400 participants were subjected to amyloid PET to select a final subgroup of 1169 A β PET(+) individuals. The study is being conducted at 68 sites in the United States, Canada, Australia, and Japan. For the present study, a subset of

RESEARCH IN CONTEXT

- 1. Systematic review:** The authors reviewed literature on plasma biomarkers in Alzheimer's disease (AD) using PubMed. This search focused on the performance of plasma amyloid beta (A β)₄₂/A β ₄₀ in large multicentric studies. Though several efforts are made to harmonize plasma-obtaining procedures, information about the impact of pre-analytical variability on the performance of plasma A β ₄₂/A β ₄₀ to predict brain A β positivity is lacking.
- 2. Interpretation:** Findings suggest that plasma A β ₄₂/A β ₄₀ accurately identifies brain amyloid deposition in cognitively unimpaired individuals from the multicentric Anti-Amyloid Treatment in Asymptomatic Alzheimer's (A4) Study. These results highlight the potential value of a plasma biomarker-based models to reduce recruitment costs in AD secondary prevention trials. Nevertheless, pre-analytical variability could have a platform-dependent influence in the performance of A β ₄₂/A β ₄₀.
- 3. Future directions:** Further research is needed to validate these findings in other multicentric studies and to elucidate the unequal impact of pre-analytical variability on different technologies. Blood biomarkers monitoring under real-life settings will require highly robust analytical procedures.

731 participants screened at 60 sites in the United States and Canada for inclusion in the A4 trial were considered.

2.2 | Amyloid PET imaging

PET imaging was acquired 50 to 70 minutes after an injection of 10 mCi of ¹⁸F-Florbetapir and measured using a mean cortical standardized uptake value ratio (SUVR) with a whole cerebellar reference region.²⁵ A SUVR threshold of ≥ 1.15 was used to define elevated amyloid.

2.3 | Pre-analytical sample handling

Plasma samples were derived from whole blood samples collected at the site in 10 mL K2-EDTA tubes, and shipped overnight on cold packs to Rissman Laboratory Biomarker Core at the University of California, San Diego (UCSD). Whole blood samples were centrifuged (2000 \times g, 10 minutes, room temperature) within 24 hours, to separate the plasma. Plasma was then aliquoted and frozen at -80°C . Plasma samples from the second screening visit arrived frozen at Araclon Biotech (Zaragoza, Spain).

2.4 | Plasma A β measurements

Plasma A β ₄₀ and A β ₄₂ concentrations were measured using ABtest-MS, an antibody-free HPLC-differential mobility spectrometry-triple quadrupole mass-spectrometry (HPLC-DMS-MS/MS) method (Araclon Biotech, Zaragoza, Spain).²⁸ Calibration curves were prepared in human plasma after spiking with ¹⁵N-A β ₄₀ and ¹⁵N-A β ₄₂ (rPeptide) at seven concentration levels. Quality control samples were also prepared in human plasma at three concentration levels (150/30, 400/75, and 750/150 pg/mL for ¹⁵N-A β ₄₀ and ¹⁵N-A β ₄₂, respectively). Calibration ranges were 50 to 1000 pg/mL for ¹⁵N-A β ₄₀ and 10 to 200 pg/mL for ¹⁵N-A β ₄₂. Two calibration curves were used in each analytical run, one at the beginning and one at the end of the sequence. Additionally, six quality control samples (three concentration levels per duplicate), uniformly distributed along the sequence, were analysed in each run. Analytes were extracted directly from plasma as no IP procedure was followed. Intact A β ₄₀ and A β ₄₂ species were measured as no enzymatic digestion was performed. Deuterated internal standards (²H-A β ₄₀ and ²H-A β ₄₂, Bachem AG) were spiked in all samples and response ratios corresponding to the endogenous species in study samples (¹⁴N-A β ₄₀/²H-A β ₄₀ and ¹⁴N-A β ₄₂/²H-A β ₄₂) were interpolated in the calibration curves. Plasma samples were analyzed in 13 analytical runs, between March 19, 2021 and May 25, 2021. Accuracy and precision values for back-calculated concentrations of calibrators and quality control samples are shown in Tables S1 and S2 in supporting information. Further details about the analytical procedure and instrumental acquisition parameters are described in the literature.²⁸ The specifics of the method are subject matter of patent application (EP2020382352).

2.5 | Cognitive testing

Participants underwent a neuropsychological test battery as part of the clinical evaluations. For this study, data regarding performance in the Mini-Mental State Examination (MMSE) and the Preclinical Alzheimer Cognitive Composite (PACC) were examined. The PACC is a well-validated composite and sensitive to the earliest signs of cognitive decline. It includes four components: MMSE, Digit Symbol Substitution Test, Logical Memory IIa Delayed Recall, and Free and Cued Selective Reminding Tests.²⁹⁻³¹

2.6 | Statistical analysis

All statistical analyses and data visualizations were carried out using GraphPad Prism v5.03 (GraphPad Software), SPSS v18 (IBM), or R (www.r-project.org). Group differences were examined using the Mann-Whitney or Kruskal-Wallis, and chi-square tests for continuous and categorical variables, respectively. Spearman correlation coefficient (rho) was used to investigate correlations between continuous variables. Logistic regression models and receiver operating characteristic (ROC) curves were constructed to evaluate the discriminative accuracy of A β PET status. Logistic regression model selection was

performed based on Akaike information criterion (AIC)³² values, that is, the most parsimonious nested model was selected. A β PET status (dichotomized) was used as the dependent variable. A reduction of two units in the AIC values was considered significant.³³ Reductions of less than two units in the AIC were further reconfirmed by the likelihood-ratio test. Area under the curve (AUC) values, obtained after ROC analyses, between selected models were compared using the DeLong test. Significance level was set at $P < 0.05$.

3 | RESULTS

3.1 | Participant characteristics

Demographic, clinical, as well as plasma biomarker data of study participants are presented in Table 1. Among the 731 individuals included in this study, 241 (33%) were classified as A β PET(+) according to the established cutoff of $SUVR \geq 1.15$ for ¹⁸F-Florbetapir. Median age for the studied population was 70.4 years (interquartile range [IQR] = 67.5–74.5) and no statistically significant difference was found between A β PET(+) and A β PET(–) individuals ($P = 0.123$). Number of APOE $\epsilon 4$ alleles (from now on, APOE $\epsilon 4$) was differentially distributed between A β PET(+) and A β PET(–) groups ($P < 0.001$). MMSE scores did not differ between A β PET status ($P = 0.094$). PACC values differed between groups, with A β PET(+) individuals performing worse ($P = 0.009$).

3.2 | Association of plasma biomarkers with brain amyloid deposition

Logarithmic transformations of plasma biomarker values were used in the analyses due to the absence of normality in the distributions. No statistically significant differences were found in A $\beta 40$ plasma levels between A β PET(+) and A β PET(–) groups ($P = 0.130$, Figure 1A). Significant differences were found for A $\beta 42$ and A $\beta 42/A\beta 40$ between the A β PET(+) and A β PET(–) groups ($P < 0.001$, Figure 1B and C). According to the median values, plasma A $\beta 42/A\beta 40$ was 13.3% lower in the A β PET(+) than in the A β PET(–) group ($P < 0.001$). Both A $\beta 42$ and A $\beta 42/A\beta 40$ showed significant negative correlations with ¹⁸F-Florbetapir-PET SUVR values ($\rho = -0.35$ and -0.44 respectively, $P < 0.001$; Figure 1D–F).

3.3 | Effect of recruitment site in A $\beta 42/A\beta 40$ measures

Taking into account that blood samples were collected, and initially stored, in multiple recruitment centers across the United States and Canada, we evaluated if this site multiplicity could produce a significant degree of pre-analytical variability, affecting A $\beta 42/A\beta 40$ measures. Site information was missing for 10 participants, and centers contributed with uneven number of participants (range 1 to 49, Table S3

in supporting information). Kruskal–Wallis analysis was carried out excluding sites contributing with only one ($n = 4$) or two ($n = 2$) volunteers. Data from 713 out of 731 participants were used in the calculations. Significant differences ($P = 0.034$) were found in A $\beta 42/A\beta 40$ values between different recruitment sites (Figure S1 in supporting information). This observation led us to include this variable in the regression models to account for this variability.

3.4 | Logistic regression and ROC analysis

Logistic regression models for predicting A β PET status were built. The following predictors (independent variables) were used: A $\beta 42/A\beta 40$, age, APOE $\epsilon 4$, sex, and MMSE and PACC scores. Multiple models were developed (Table 2 and Table S4 in supporting information). The most parsimonious model yielding a minimum AIC value (709.120) was composed of A $\beta 42/A\beta 40$ ratio, age, APOE $\epsilon 4$, and site (Model 7). The inclusion of PACC in the model produced a non-significant decrease in AIC (0.54 units, Model 12) and therefore this neuropsychological test was removed from the final model. A baseline (demographic) model containing all of the above predictors with the exception of A $\beta 42/A\beta 40$ ratio yielded an AIC value of 838.082 (Model 4).

ROC analysis was performed to assess the predictive ability of the different models to identify brain amyloid deposition (Figure 2 and Table 2; selected models are shown in Figure 2). Baseline model, including age, APOE $\epsilon 4$, and site yielded an AUC value of 0.80 (95% confidence interval [CI] 0.77–0.84). The inclusion of A $\beta 42/A\beta 40$ ratio in the model (Full model, Model 7 in Table 2) increased the AUC to 0.88 (95% CI 0.86–0.91). This increase in AUC is considered statistically significant according to the DeLong test. Applying a cutoff value of 0.303 (calculated at maximum Youden index), this model yielded a sensitivity of 87%, a specificity of 78%, and an overall accuracy of 81% (Figure 3A). Median probability scores derived from the full predictive model were highly different between A β PET(+) and A β PET(–) individuals (0.636 vs. 0.102, $P < 0.001$, Figure 3B).

3.5 | Heat maps

Heat maps showing the predicted probability of being A β PET(+) based on plasma A $\beta 42/A\beta 40$ measures (y axis) and age (x axis), stratified by APOE $\epsilon 4$ genotype, were generated (Figure 4). As an example, a 75-year-old individual bearing no APOE $\epsilon 4$ allele and with an A $\beta 42/A\beta 40$ value of 0.25, has a 42.7% probability of being A β PET(+), while the same individual bearing at least one APOE $\epsilon 4$ allele has a probability of 66.6%.

3.6 | Savings in the number of PET scans

The feasibility of applying ABtest-MS as a pre-screening tool in clinical trials was also evaluated. As an example, to obtain 1000 A β PET(+) CU individuals as in the A4 Study, 3030 PET scans should be necessary

TABLE 1 Participant characteristics.^a

	A β PET(-) ^b	A β PET(+) ^b	Total	P value
Participants, N (%)	490 (67)	241 (33)	731	
Age (years)				0.123
Median	70.3	70.6	70.4	
Q1–Q3	67.5–74.3	67.8–75.22	67.5–74.5	
Sex, N (%)				0.899
Male	207 (42.2)	103 (42.7)	310 (42.4)	
Female	283 (57.8)	138 (57.3)	421 (57.6)	
APOE ϵ 4, N (%)				<0.001
0 alleles	371 (75.7)	99 (41.0)	470 (64.3)	
1 allele	110 (22.4)	120 (49.8)	330 (45.1)	
2 alleles	9 (1.8)	22 (9.1)	31 (4.2)	
MMSE				0.094
Median	29	29	29	
Q1–Q3	28–30	28–30	28–30	
PACC				0.009
Median	0.36	-0.19	0.16	
Q1–Q3	-1.48–2.00	-2.12–1.55	-1.58–1.86	
Florbetapir-PET SUVr				<0.001
Median	1.03	1.29	1.08	
Q1–Q3	0.97–1.08	1.21–1.40	1.00–1.21	
A β 40 (pg/mL)				0.130
Median	201.5	209.2	204.3	
Q1–Q3	181.9–230.9	180.8–236.2	181.1–232.6	
A β 42 (pg/mL)				<0.001
Median	61.2	52.9	58.0	
Q1–Q3	53.7–69.1	46.8–59.4	51.0–67.1	
A β 42/A β 40				<0.001
Median	0.30	0.26	0.28	
Q1–Q3	0.27–0.33	0.23–0.28	0.25–0.32	

Abbreviations: A β , amyloid beta; APOE, apolipoprotein E; MMSE, Mini-Mental State Examination; PACC, Preclinical Alzheimer Cognitive Composite; PET, positron emission tomography; Q, quartile; SUVr, standardized uptake value ratio.

^aData are median values (interquartile range) except for sex and APOE ϵ 4 number of alleles, which are number of cases and percentages. Differences between groups A β PET(-) and A β PET(+) groups were tested using Mann–Whitney and chi-square test, as appropriate.

^bA β -PET status was defined using the cutoff of SUVr \geq 1.15 for ¹⁸F-Florbetapir.

according to a population with a prevalence for A β PET(+) of 33%. A predictive model taking into account plasma A β 42/A β 40 ratio, number of APOE ϵ 4 alleles, and the age of the patient could significantly reduce the number of PET scans. Using data from this work, the predictive model shown above (Model 6 in Table 2; Figures 3C and 3D) yields a sensitivity of 81%, a specificity of 70%, an accuracy of 74%, a positive predictive value (PPV) of 57%, and a negative predictive value (NPV) of 88%. Considering these figures, 3741 individuals should be necessary for blood analysis, of which 1754 should undergo PET imaging (instead of 3030), resulting in a net savings of 42% of the scans. Assuming an

average cost of \$3000 to \$6000 per PET scan,^{34,35} several million dollars could be saved in large studies such as A4. In addition, recruitment time could be greatly reduced.

4 | DISCUSSION

In this work, we have evaluated the performance of ABtest-MS, a direct extraction protocol coupled to MicroLC-DMS-MS/MS for the quantitation of A β 40 and A β 42 in plasma, in a large international and




FIGURE 1 Distribution of plasma biomarkers between Aβ PET(–) and Aβ PET(+) groups and correlation of plasma biomarkers with brain amyloid deposition. Distribution of plasma Aβ40 (A), Aβ42 (B), and Aβ42/Aβ40 (C) between Aβ PET(–) and Aβ PET(+) groups. Group comparisons were carried out using a Mann–Whitney test. Correlations for Aβ40 (D), Aβ42 (E), and Aβ42/Aβ40 (F) and ¹⁸F-Florbetapir SUVR values. Dashed lines represent 95% confidence intervals. ****P* < 0.001. Aβ, amyloid beta; n.s., non-significant; PET, positron emission tomography; SUVR, standardized uptake value ratio.




FIGURE 2 Predictive ability of different regression models for identifying Aβ PET status. ROC curves for discriminating Aβ PET status. Five regression models from the 12 shown in Table 2 are selected for representation. The model with highest AUC and accuracy, as well as lowest AIC, includes Aβ42/Aβ40, age, number of APOE ε4 alleles, and recruitment site. AIC, Akaike information criterion; APOE, apolipoprotein E; AUC, area under the ROC curve; PET, positron emission tomography; ROC, receiver operating characteristic.

multicentric study, an environment that much better reflects real-world conditions than small, single-center studies in which variability associated with sample handling, storage, and transportation should be lower.

As expected, plasma Aβ42/Aβ40 was reduced in Aβ PET(+) individuals, being 13.3% lower than in Aβ PET(–) counterparts. This observed reduction is in good agreement with previously reported works.¹⁸ The small differences in plasma Aβ42/Aβ40 values between Aβ PET(+) and Aβ PET(–) groups suggest that the use of high reliability analytical procedures is critical. Method robustness and analytical repeatability are needed for the analysis of amyloid peptides in plasma; otherwise, small analytical drifts could dramatically change the outcome of the assay.^{18,19}

The full descriptive model (including Aβ42/Aβ40, age, APOE ε4, and recruitment site), outperformed the most complete demographic model, which included all the above covariates, with the exception of plasma Aβ42/Aβ40 ratio. The best model, in terms of AIC, yielded the highest AUC value and the highest accuracy. The inclusion of the number of APOE ε4 alleles and age in any predictive model for identification of brain amyloid status is well justified,^{36–41} as these are two well-known risk factors for AD and additive to plasma Aβ42/Aβ40 ratio. The obtained predictive model (Aβ42/Aβ40, age, and APOE ε4) is frequently reported in the literature,⁴² identifying age and the presence of APOE ε4 alleles as risk factors for brain amyloid deposition. An AUC value of 0.82 obtained in this study is in good agreement with those recently reported in a comparative study for IP-MS (0.78–0.84) and immunoassays (0.77–0.81) in an Alzheimer's Disease Neuroimaging Initiative dataset.⁴³

The inclusion of recruitment site in the model corrects, at least partially, the heterogeneity introduced by such a large number of sites. Other authors have adopted similar approaches in multi-cohort

TABLE 2 Logistic regression model diagnostics.

Model	Covariates	AIC	pseudo-r ²	AUC	95% CI
1	Age, sex, APOE ε4, MMSE	836.984	0.180	0.72	0.68–0.76
2	Age, APOE ε4, MMSE	835.131	0.180	0.72	0.68–0.76
3	Age, APOE ε4	837.008	0.174	0.71	0.67–0.75
4	Age, APOE ε4, site	838.082	0.337	0.80	0.77–0.84
5	Ratio	763.842	0.284	0.78	0.75–0.82
6	Ratio, age, APOE ε4 ^a	716.767	0.362	0.82	0.79–0.85
7	Ratio, age, APOE ε4, site ^b	709.120	0.513	0.88	0.86–0.91
8	Age, sex, APOE ε4, PACC	832.916	0.188	0.72	0.68–0.76
9	Age, APOE ε4, PACC	831.425	0.187	0.72	0.68–0.76
10	Ratio, age, APOE ε4, PACC	714.964	0.367	0.82	0.79–0.85
11	Age, APOE ε4, site, PACC	834.027	0.346	0.81	0.77–0.84
12	Ratio, age, APOE ε4, site, PACC	708.578	0.516	0.88	0.86–0.91

Abbreviations: AIC, Akaike information criterion; APOE, apolipoprotein E; AUC, area under the curve; CI, confidence interval; MMSE, Mini-Mental State Examination; PACC, Preclinical Alzheimer Cognitive Composite; Site, recruitment site.

Note: Logistic regression model fit was evaluated according to AIC, where a lower value means a better fit after a correction for overparameterization. Pseudo-r² values correspond to Nagelkerke r² values. 95% CI for each AUC value are also shown. ΔAIC between Model 12 and Model 7 (0.542) is not considered significant according to a likelihood-ratio test ($P = 0.05$ and 1 degree of freedom), so PACC was not included in the final model.

^aAUC from Model 6 is statistically different from that of Model 3, according to the DeLong test ($P < 0.001$).

^bAUC from model 7 is statistically different from that of Model 4, according to the DeLong test ($P < 0.001$).

studies.^{44,45} Accordingly, the full model, which includes this covariate, yields a much better separation between Aβ PET(+) and Aβ PET(−) subjects, improving clinical robustness of the plasma biomarker. Contribution of this covariate in the performance of regression models could be impacted by the unequal distribution of participants per center, as well as by different factors that are part of pre-analytical variability.

Regarding this last point, a recent study has revealed large differences in the predictive value of plasma Aβ42/Aβ40 when two different plasma collection protocols were applied in A4 samples.²⁴ Although a direct comparison is not possible, because the same samples have not been analyzed, when plasma samples were processed within 24 hours from blood extraction, the C2N's IP-LC-MS/MS technology identified amyloid-PET status with an AUC of 0.64, notably worse than the 0.78 reported by ABtest-MS in the present study in plasma samples processed with the same protocol. On the other hand, in the study by Winston et al.,²⁴ a dataset of 224 plasma samples was processed within 2 hours from blood extraction and analyzed by Shimadzu's and C2N's platforms. In this case, the AUCs for amyloid-PET status were 0.80 and 0.76, respectively, which were comparable to the performance reported by ABtest-MS in plasma samples processed within 24 hours. These results reflect that the impact of pre-analytical variables on the final performance of the biomarker is highly dependent of the analytical methodology used, and consequently, suggest that ABtest-MS may be a more robust approach for the analysis of plasma Aβ42/Aβ40 under a variety of pre-analytical conditions such as delayed blood processing.

The impact of pre-analytical variables on Aβ40 and Aβ42 levels has been investigated in other studies. Unlike Winston et al.,²⁴ Verberk et al.²¹ observed that storage of blood samples up to 24 hours at 4°C before centrifugation does not have an impact on Aβ levels. Further

studies should address the potential causes of these observed variations and compare the sensitivity of different platforms, for example, platforms that include an immunocapture step versus platforms such as ABtest-MS that does not, to this pre-analytical variable.

According to the concordance plot, it is observed that there were many more false positive than false negative predictions. Most of the discordant cases (78%) were plasma Aβ42/Aβ40(+), according to a threshold of 0.303, but Aβ PET(−). This observation has been interpreted as the plasma ratio being an earlier biomarker of brain amyloid deposition than PET itself, that is, CSF and plasma ratio values begin to decrease before amyloid accumulation is detected by PET imaging.⁴⁶

There is a common agreement in the difficulty of the analysis of Aβ peptides in human plasma.^{47,48} Hydrophobicity and self-aggregating properties of these peptides suppose an analytical challenge. Besides this, interferences with plasma components (the so-called matrix effect) may impact analytical reproducibility. Methods including an immunocapture step are more prone to show matrix effects than those procedures which avoid it. These effects may be more detrimental in immunoassays than in MS-based methods, as the latter usually include a solid phase extraction step for analyte purification. In our opinion, antibody-free, direct extraction methods are faster and more robust in terms of sample preparation. Moreover, a significant increase in sample throughput and a reduction in cost per sample is achieved, making the assay much more affordable. All these results demonstrate that ABtest-MS is a useful and accurate tool for the identification of brain amyloid deposition in CU individuals, even in large and heterogeneous datasets.

In the last few years, trials are being conducted in the early stages of the disease, even in asymptomatic individuals, when the prevalence of amyloid positivity is very low. The use of an accurate blood test




FIGURE 3 Concordance plots and distributions of model-derived probabilities between A β PET(-) and A β PET(+) groups. A, Concordance plot between ^{18}F -Florbetapir SUVR and derived probabilities of the regression model including A β 42/A β 40, age, number of APOE ϵ 4 alleles, and recruitment site. Dashed lines represent cutoffs for SUVR (vertical) or probability at Youden maximum index (horizontal). B, Distribution of predicted probabilities between A β PET(-) and A β PET(+) groups for the model described above (A). Group comparisons were carried out using a Mann-Whitney test (** $P < 0.001$). Values exceeding median value $\pm 1.5 \times$ interquartile range (IQR) are displayed as outliers. C, Concordance plot between ^{18}F -Florbetapir SUVR and derived probabilities of the regression model including A β 42/A β 40, age, and number of APOE ϵ 4 alleles. Dashed lines represent cutoffs as in (A). D, Distribution of predicted probabilities between A β PET(-) and A β PET(+) groups for the model described above (C). Group comparisons were carried out using a Mann-Whitney test (** $P < 0.001$). Values exceeding median value $\pm 1.5 \times$ IQR are displayed as outliers. A β , amyloid beta; APOE, apolipoprotein E; PET, positron emission tomography; SUVR, standardized uptake value ratio.

applying cutoff values which maximize PPV could provide a significant reduction of the number of PET scans or lumbar punctures^{34,49,50} needed to select the desired population of A β PET(+) individuals. Additionally, recruitment time (3.5 years for the A4 Study⁶) would be dramatically reduced, providing a clear benefit not only for study sponsors, but mainly patients, relatives, and caregivers.

The main limitation of this work is the availability of data from a single blood biomarker. Though it is commonly accepted that A β peptides show one of the earliest changes among the current biomarker panel, combinations of several biomarkers (i.e., A β 42/ A β 40 and phosphorylated tau) could be of great help for the identification of CU individuals who are in the initial stages of brain amyloid accumulation.

Another limitation is the overwhelming majority of White participants (92% of the 4486 participants in the second screening visit and 94% in this dataset), which can add complexity to the generalization

of the results to real-world settings. Further studies should address potential differences in the performance of blood tests across different racial groups.

To conclude, in this work, we have demonstrated that ABtest-MS, a direct extraction protocol coupled to LC-MS for the quantitation of A β 40 and A β 42 in plasma samples, accurately identifies brain amyloid deposition in a population of CU individuals from the second screening visit of the A4 Study, despite the high heterogeneity inherent to large and multicentric clinical trials. Unlike other platforms, ABtest-MS has demonstrated high robustness for plasma A β 42/A β 40 performance when plasma is obtained up to 24 hours after blood extraction, outperforming IP-MS methodology. A predictive model based on plasma A β 42/A β 40, number of APOE ϵ 4 alleles, and the age of the patient, could provide significant savings in time and cost for the clinical trial recruitment step.




FIGURE 4 Heat maps showing predicted probability of being Aβ PET(+) according to age (horizontal axis) and Aβ42/Aβ40 plasma values (vertical axis) for those subjects bearing at least one APOE ε4 allele (left) and APOE ε4 non-carriers (right). Predicted probabilities are displayed in percentages. 95% confidence intervals are indicated between brackets. Aβ, amyloid beta; APOE, apolipoprotein E; PET, positron emission tomography.

ACKNOWLEDGMENTS

The authors thank Dr. Reisa Sperling and Dr. Paul Aisen (A4 Study PIs), the A4 Study Team at USC ATRI, the A4 Study sites, and the participants of the A4 Trial. This work was supported by NIH/NIA R01 grants AG058252, AG073979, AG051848 to RAR and biomarker core funds to RAR from AG057437 (USC ACTC), and AG010483 (UCSD ADCS).

CONFLICT OF INTEREST STATEMENT

J.A.A., M.P.L., L.S., S.C., and J.T. are full-time employees at Araclon Biotech-Grifols. M.E.S. is a statistical consultant at Caebi. R.A.R. and S.A.L. have no conflicts of interest relevant to this study. Author disclosures are available in the [supporting information](#).

CONSENT STATEMENT

All human subjects provided informed consent.

ORCID

José Antonio Allué  <https://orcid.org/0000-0002-5690-3618>

REFERENCES

- Jack CR Jr, Holtzman DM. Biomarker modeling of Alzheimer's disease. *Neuron*. 2013;80(6):1347-1358.
- Rasmussen J, Langerman H. Alzheimer's disease - why we need early diagnosis. *Degener Neurol Neuromuscul Dis*. 2019;9:123-130.
- Karikari TK, Benedet AL, Ashton NJ, et al. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's disease neuroimaging initiative. *Mol Psychiatry*. 2021;26(2):429-442.
- Teunissen CE, Verberk IMW, Thijssen EH, et al. Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. *Lancet Neurol*. 2022;21(1):66-77.
- Cummings J, Feldman HH, Scheltens P. The "rights" of precision drug development for Alzheimer's disease. *Alzheimers Res Ther*. 2019;11(1):76.
- Aisen PS, Jimenez-Maggiora GA, Rafii MS, Walter S, Raman R. Early-stage Alzheimer disease: getting trial-ready. *Nat Rev Neurol*. 2022;18(7):389-399.
- Langbaum JB, Zissimopoulos J, Au R, et al. Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials. *Alzheimers Dement*. 2023;19(2):696-707.
- Janssen O, Jansen WJ, Tijms BM, et al. Updated prevalence estimates of amyloid positivity from cognitively normal to clinical Alzheimer's disease dementia: the amyloid biomarker study. *Alzheimer's Dement*. 2021;17(S10):e054889.
- Zetterberg H, Burnham SC. Blood-based molecular biomarkers for Alzheimer's disease. *Molecular brain*. 2019;12(1):26.
- Budelier MM, Bateman RJ. Biomarkers of Alzheimer disease. *J Appl Lab Med*. 2020;5(1):194-208.
- Cullen NC, Leuzy A, Palmqvist S, et al. Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. *Nat Aging*. 2021;1(1):114-123.
- Schindler SE, Bateman RJ. Combining blood-based biomarkers to predict risk for Alzheimer's disease dementia. *Nature Aging*. 2021;1(1):26-28.
- Leuzy A, Mattsson-Carlgrén N, Palmqvist S, Janelidze S, Dage JL, Hansson O. Blood-based biomarkers for Alzheimer's disease. *EMBO Mol Med*. 2022;14(1):e14408.
- Hansson O, Edelmayer RM, Boxer AL, et al. The Alzheimer's association appropriate use recommendations for blood biomarkers in Alzheimer's disease. *Alzheimers Dement*. 2022;18(12):2669-2686.

15. Fandos N, Pérez-Grijalba V, Pesini P, et al. Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals. *Alzheimers Dement*. 2017;8:179-187.
16. Blennow K, Zetterberg H. Biomarkers for Alzheimer's disease: current status and prospects for the future. *J Intern Med*. 2018;284(6):643-663.
17. Pérez-Grijalba V, Romero J, Pesini P, et al. Plasma A β 42/40 ratio detects early stages of Alzheimer's disease and correlates with CSF and neuroimaging biomarkers in the AB255 study. *J Prev Alzheimers Dis*. 2019;6(1):34-41.
18. Rabe C, Bittner T, Jethwa A, et al. Clinical performance and robustness evaluation of plasma amyloid-beta(42/40) prescreening. *Alzheimers Dement*. 2023;19(4):1393-1402.
19. Benedet AL, Brum WS, Hansson O, et al. The accuracy and robustness of plasma biomarker models for amyloid PET positivity. *Alzheimers Res Ther*. 2022;14(1):26.
20. Lippi G, Banfi G, Church S, et al. Preanalytical quality improvement. In pursuit of harmony, on behalf of European Federation for Clinical Chemistry and Laboratory Medicine (EFLM) working group for Preanalytical Phase (WG-PRE). *Clin Chem Lab Med*. 2015;53(3):357-370.
21. Verberk IMW, Misdorp EO, Koelewijn J, et al. Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease-related blood-based biomarkers: results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group. *Alzheimers Dement*. 2022;18(8):1484-1497.
22. Janelidze S, Palmqvist S, Leuzy A, et al. Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Abeta42/Abeta40 and p-tau. *Alzheimers Dement*. 2022;18(2):283-293.
23. Jang H, Kim JS, Lee HJ, et al. Performance of the plasma A β 42/A β 40 ratio, measured with a novel HPLC-MS/MS method, as a biomarker of amyloid PET status in a DPUK-KOREAN cohort. *Alzheimers Res Ther*. 2021;13(1):179.
24. Winston CN, Langford O, Levin N, et al. Evaluation of blood-based plasma biomarkers as potential markers of amyloid burden in preclinical Alzheimer's disease. *J Alzheimers Dis*. 2023;92(1):95-107.
25. Sperling RA, Donohue MC, Raman R, et al. Association of factors with elevated amyloid burden in clinically normal older individuals. *JAMA Neurol*. 2020;77(6):735-745.
26. Insel PS, Donohue MC, Sperling R, Hansson O, Mattsson-Carlsson N. The A4 study: β -amyloid and cognition in 4432 cognitively unimpaired adults. *Ann Clin Transl Neurol*. 2020;7(5):776-785.
27. Sperling RA, Rentz DM, Johnson KA, et al. The A4 study: stopping AD before symptoms begin? *Sci Transl Med*. 2014;6(228):228fs13.
28. Pascual-Lucas M, Allué JA, Sarasa L, et al. Clinical performance of an antibody-free assay for plasma A β 42/A β 40 to detect early alterations of Alzheimer's disease in individuals with subjective cognitive decline. *Alzheimers Res Ther*. 2023;15(1):2.
29. Donohue MC, Sperling RA, Salmon DP, et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. *JAMA Neurol*. 2014;71(8):961-970.
30. Mormino EC, Papp KV, Rentz DM, et al. Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β . *Alzheimers Dement*. 2017;13(9):1004-1012.
31. Bransby L, Lim YY, Ames D, et al. Sensitivity of a Preclinical Alzheimer's Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer's disease. *J Clin Exp Neuropsychol*. 2019;41(6):591-600.
32. Akaike H. A new look at the statistical model identification. *IEEE Trans Autom Control*. 1974;19(6):716-723.
33. Burnham KP, Anderson DR. Multimodel inference: understanding AIC and BIC in model selection. *SMR*. 2004;33(2):261-304.
34. Schindler SE, Li Y, Li M, et al. Using Alzheimer's disease blood tests to accelerate clinical trial enrollment. *Alzheimers Dement*. 2023;19(4):1175-1183.
35. Poslusny C. How much does a PET scan cost?: New Choice Health. Available from: <https://www.newchoicehealth.com/pet-scan/cost>
36. Roses AD. Apolipoprotein E alleles as risk factors in Alzheimer's disease. *Annu Rev Med*. 1996;47:387-400.
37. Stocker H, Möllers T, Perna L, Brenner H. The genetic risk of Alzheimer's disease beyond APOE ϵ 4: systematic review of Alzheimer's genetic risk scores. *Transl Psychiatry*. 2018;8(1):166.
38. Tsai MS, Tangalos EG, Petersen RC, et al. Apolipoprotein E: risk factor for Alzheimer disease. *Am J Hum Genet*. 1994;54(4):643-649.
39. Povova J, Ambroz P, Bar M, et al. Epidemiological of and risk factors for Alzheimer's disease: a review. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub*. 2012;156(2):108-114.
40. Armstrong RA. Risk factors for Alzheimer's disease. *Folia Neuropathol*. 2019;57(2):87-105.
41. Guerreiro R, Bras J. The age factor in Alzheimer's disease. *Genome med*. 2015;7:106.
42. Hu Y, Kirmess KM, Meyer MR, et al. Assessment of a plasma amyloid probability score to estimate amyloid positron emission tomography findings among adults with cognitive impairment. *JAMA network open*. 2022;5(4):e228392.
43. Zicha S, Bateman RJ, Shaw LM, et al. Comparative analytical performance of multiple plasma A β 42 and A β 40 assays and their ability to predict positron emission tomography amyloid positivity. *Alzheimer's Dement*. 2023;19:956-966. <https://doi.org/10.1002/alz.12697>
44. West T, Kirmess KM, Meyer MR, et al. A blood-based diagnostic test incorporating plasma A β 42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis. *Mol Neurodegener*. 2021;16(1):30.
45. Ossenkoppele R, Pichet Binette A, Groot C, et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. *Nat Med*. 2022;28(11):2381-2387.
46. Schindler SE, Bollinger JG, Ovod V, et al. High-precision plasma β -amyloid 42/40 predicts current and future brain amyloidosis. *Neurology*. 2019;93(17):e1647-e59.
47. Pannee J, Shaw LM, Korecka M, et al. The global Alzheimer's association round robin study on plasma amyloid β methods. *Alzheimers Dement*. 2021;13(1):e12242.
48. Udeh-Momoh C, Zheng B, Sandebring-Matton A, et al. Blood derived amyloid biomarkers for Alzheimer's disease prevention. *J Prev Alzheimers Dis*. 2022;9(1):12-21.
49. Keshavan A, Pannee J, Karikari TK, et al. Population-based blood screening for preclinical Alzheimer's disease in a British birth cohort at age 70. *Brain*. 2021;144(2):434-449.
50. Wittenberg R, Knapp M, Karagiannidou M, Dickson J, Schott J. Economic impacts of introducing diagnostics for mild cognitive impairment Alzheimer's disease patients. *Alzheimers Dement (N Y)*. 2019;5:382-387.

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Allué JA, Pascual-Lucas M, Sarasa L, et al. Clinical utility of an antibody-free LC-MS method to detect brain amyloid deposition in cognitively unimpaired individuals from the screening visit of the A4 Study. *Alzheimer's Dement*. 2023;15:e12451. <https://doi.org/10.1002/dad2.12451>